<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291004</url>
  </required_header>
  <id_info>
    <org_study_id>DSG-OI-101</org_study_id>
    <nct_id>NCT01291004</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives</brief_title>
  <official_title>A Multicenter, Open-label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared
      to two 28-day oral contraceptive regimens containing different synthetic progestins on
      ovarian follicular activity and hormone levels in healthy women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of ovarian follicular development by the Hoogland and Skouby grading scale from baseline to week 16.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum Estradiol level from baseline to week 16.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) levels from baseline to week 16.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum Progesterone level from baseline to week 20.</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in Prothrombin fragment 1 + 2 levels.</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in D-dimer.</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to end of week 15 in Plasmin-Antiplasmin complex</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in APTT and ETP based activated protein-C resistance (APC).</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in Fibrinogen.</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in Plasminogen, Factor II, Factor VII, Factor VIII, Protein C, and Free and Total Protein S.</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in Tissue Plasminogen Activator (t-PA).</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in Antithrombin.</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in Tissue Factor Pathway Inhibitor (TFPI).</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in Total Cortisol and Corticosteroid Binding Globulin (CBG).</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in Thyroid Stimulating Hormone (TSH).</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 15 in Sex Hormone Binding Globulin (SHBG).</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to ovulation rate at week 20.</measure>
    <time_frame>Week 20</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Follicle Development</condition>
  <condition>Ovarian Follicle</condition>
  <condition>Follicle Count</condition>
  <condition>Follicle Size</condition>
  <condition>Oral Contraceptive</condition>
  <arm_group>
    <arm_group_label>28-day Desogestrel Oral Contraceptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>28-day Drospirenone Oral Contraceptive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>28-day Levonorgestrel Oral Contraceptive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogestrel/ethinyl estradiol and ethinyl estradiol</intervention_name>
    <description>Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet</description>
    <arm_group_label>28-day Desogestrel Oral Contraceptive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>28-day drospirenone oral contraceptive</intervention_name>
    <description>Drospirenone/ethinyl estradiol 0.3/0.02 mg</description>
    <arm_group_label>28-day Drospirenone Oral Contraceptive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>28-day levonorgestrel oral contraceptive</intervention_name>
    <description>Levonorgestrel/ethinyl estradiol 0.1/0.02 mg</description>
    <arm_group_label>28-day Levonorgestrel Oral Contraceptive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal, non-pregnant, non-lactating women age 18-35 years old

          -  Body Mass Index (BMI) ≥18 kg/m² and &lt;30 kg/m²

          -  Regular spontaneous menstrual cycle

          -  Others as dictated by Food and Drug Administration (FDA)-approved protocol

        Exclusion Criteria:

          -  Any condition which contraindicates the use of combination oral contraceptives

          -  Known thrombophlebitis or thromboembolic disorders; known or suspected clotting
             disorders; thrombogenic valvulopathies or rhythm disorders

          -  Migraine headaches with focal, neurological symptoms

          -  Others as dictated by FDA-approved protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Women's Health Research Protocol Chair</last_name>
    <role>Study Chair</role>
    <affiliation>Teva Branded Pharmaceutical Products, R&amp;D Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

